Investigating how cancer cells resist treatment and spread in the body
Tumor-cell intrinsic and extrinsic determinants of drug resistance and metastasis
This study is looking into why some colorectal cancer cells don't respond to treatment and how they can spread, focusing on a protein called Claudin-1, to help find new ways to fight the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10990396 on NIH RePORTER |
What this research studies
This research explores the mechanisms behind why some cancer cells become resistant to treatment and how they spread to other parts of the body. It focuses on both internal factors within the cancer cells, such as genetic changes, and external influences from the surrounding immune environment. The study will analyze the role of a specific protein, Claudin-1, in promoting resistance and metastasis in colorectal cancer, using patient samples to compare normal and cancerous tissues. By understanding these processes, the research aims to identify new targets for therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with advanced colorectal cancer.
Not a fit: Patients with early-stage cancer or those whose cancer is not colorectal may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with advanced cancer, potentially reducing metastasis and enhancing the effectiveness of therapies.
How similar studies have performed: Previous research has shown success in targeting similar mechanisms of drug resistance and metastasis in cancer, indicating a promising avenue for further exploration.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Primeaux, Mark — University of Nebraska Medical Center
- Study coordinator: Primeaux, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.